Navigation Links
Anthera's Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
Date:5/6/2009

isk patients) and maintained this lower level throughout the primary endpoint. The effect was more pronounced for patients achieving LDL-C below 50 mg/dL.

"Building on strong results from our first two clinical studies in stable cardiovascular patients, the FRANCIS study has validated the potential utility of aggressive varespladib treatment to improve outcomes in a high-risk patient population immediately following an ACS event," said Paul F. Truex, President and Chief Executive Officer of Anthera Pharmaceuticals, Inc. "In addition to meeting the primary and several secondary endpoints, clinical data from the FRANCIS study has met and/or exceeded our expectations and we hope to present the entire data set including biomarkers, safety, and secondary clinical endpoints (MACE) at an upcoming scientific conference."

"We are extremely excited by these data," said Colin Hislop, M.D., Senior Vice President Clinical Development at Anthera. "The favorable treatment effect of varespladib is consistent with our Phase 3 development plan and provides a robust data set to support substantial clinical benefit for this novel, first in class therapy."

With approximately 1000 patient exposures to date in three cardiovascular studies, varespladib has been generally well tolerated.

About the FRANCIS trial

The FRANCIS trial is based upon direct feedback from Food and Drug Administration via the Special Protocol Assessment process. FRANCIS was designed to assess the impact of oral varespladib on known biological markers of cardiovascular risk. It enrolled 625 patients who will be treated for a minimum of six months. The study is being conducted at sites in Europe. FRANCIS is designed to provide insight into the potential prevention of secondary Major Adverse Cardiovascular Events (MACE) by varespladib. In this study, MACE was defined as a composite endpoint consisting of all-cause mortali
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
2. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
3. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
4. Schering-Ploughs Investigational Oral Thrombin Receptor Antagonist Meets Primary Endpoint in a Newly Published Study
5. Isolagen, Inc. Reports Positive Top-line Results from Phase II/III Study of Isolagen Therapy(TM) to Treat Moderate to Severe Acne Scars: Study Meets All Primary Efficacy Endpoints and is Statistically Significant
6. Alexzas AZ-004 (Staccato(R) Loxapine) Meets Primary Endpoint of Treating Acute Agitation in Patients with Bipolar Disorder in Phase 3 Trial
7. TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia
8. Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinsons Disease
9. NicOx Announces Second Naproxcinod Pivotal Phase 3 Study (302) Meets Efficacy Primary Endpoints and Supports Non-Detrimental Blood Pressure Effect
10. Alexzas AZ-004 (Staccato(R) Loxapine) Phase 3 Trial Meets Primary Endpoint of Treating Acute Agitation in Schizophrenic Patients
11. Teliks Proteasome Inhibitor Program Meets a Preclinical Development Milestone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/17/2014)... Md. , Oct. 17, 2014 ... for Medical Technology Policy: The Green ... the FDA, public and private payers, medical device ... clinicians, and other experts January 12, 2015 at ... and value of weight loss treatments.  Participants will ...
(Date:10/17/2014)...   InnFocus, Inc ., reported on results of 59 ... for up to 3 years with the InnFocus MicroShunt® ... Chicago . The Summit ... of the American Academy of Ophthalmology . The Company ... patients in 6 countries by early 2015. Logo ...
(Date:10/17/2014)... Mass. , Oct. 17, 2014   ndd ... function testing (PFT) employing precise ultrasound technology, announced that ... Choctaw Nation Healthcare Center , a 140,000 square ... Talihina, Oklahoma hospital serves a large ... southeastern Oklahoma and beyond. A ...
Breaking Medicine Technology:Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2InnFocus Featured at the Ophthalmology Innovation Summit In Chicago 2EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2
... N.J., Oct. 25, 2011 Omthera Pharmaceuticals, Inc., a ... J. Maines has joined the Company as Vice President ... to Chief Operating Officer, Drs. Ben Machielse, Mr. Maines ... at Omthera.   Mr. Maines brings to ...
... N.C., Oct. 25, 2011 GlaxoSmithKline, one of ... today announced the 10 winners of its GlaxoSmithKline ... Philadelphia-area healthcare nonprofit organizations will receive $400,000 in ... the underserved in their communities. Three ...
Cached Medicine Technology:Timothy J. Maines Joins Omthera Pharmaceuticals as Vice President of Quality 2GlaxoSmithKline to Grant $400,000 to Healthcare Nonprofits at Annual IMPACT Awards 2GlaxoSmithKline to Grant $400,000 to Healthcare Nonprofits at Annual IMPACT Awards 3
(Date:10/20/2014)... Collins, CO (PRWEB) October 20, 2014 ... dGH assays are the only imaging assays capable ... in a single test.  With these three dimensions ... their ability to detect the widest range of ... translocations—mutations usually missed by other genomic tools, including ...
(Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The ... member hospital ROI on membership dues at 12.5. In other ... $12.50 in value to member hospitals. The calculation used to ... Dues. , “This is the first time we’ve actually ... the methodology is really sound,” said Bill Ryan , ...
(Date:10/20/2014)... Houston plastic surgeon Dr. Christopher ... of his innovative True Form Tummy Tuck® ... and faculty at The University of Texas Medical ... once a medical student. Patronella, who is a founding ... surgery practices in Texas, The Aesthetic Center for ...
(Date:10/19/2014)... The leading review website, Top10BestSEOHosting.com, has recently announced ... the best Dedicated Server Hosting suppliers. Their websites ... buy high quality hosting and save money at ... Top10BestSEOHosting.com says, “We believe that iPage and GreenGeeks ... lot of the global clients enjoy using their ...
(Date:10/19/2014)... 20, 2014 This report provides ... Seizure, complete with comparative analysis at various stages, ... (MoA), route of administration (RoA) and molecule type, ... press releases. It also reviews key players involved ... special features on late-stage and discontinued projects. , ...
Breaking Medicine News(10 mins):Health News:KromaTiD Launches Genome Screening and Discovery Services 2Health News:KromaTiD Launches Genome Screening and Discovery Services 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4
... , SUNDAY, March 20 (HealthDay News) -- Firstborn ... of allergies, finds a new study. Japanese researchers surveyed ... and found that a child,s birth order did not seem ... firstborn children were more likely to have hay fever, pink ...
... San Diego, Calif., USA Today, during the 89th ... Dental Research, held in conjunction with the 40th Annual ... the 35th Annual Meeting of the Canadian Association for ... oral presentation on a research study titled "Biodegradable Tooth-binding ...
... Jenifer Goodwin HealthDay Reporter , FRIDAY, March ... an advisory panel to the U.S. Food and Drug ... and their removal "from the marketplace would benefit public ... Scientific Advisory Committee also said that menthols, minty flavor ...
... -- Girls in early adolescence who form friendships with boys ... a new research. The study included 400 female and ... interviewed annually over seven years about their friendship network and ... girls tend to limit their friendships to same-sex peers. But ...
... (HealthDay News) -- Orthodontic retainers, removable devices used to keep ... if they aren,t properly cleaned, finds a new study. ... of a group of study participants and found that about ... that can cause fungal infections, while 50 percent had ...
... will likely be the hardest hit as a result of ... previous catastrophic events. Approximately 23 percent of Japanese citizens currently ... the highest proportion of older people in any country ... whole is headed," said James Appleby, RPh, MPH, executive director ...
Cached Medicine News:Health News:Biodegradable tooth-binding micelles inhibit Streptococcus mutans biofilm growth 2Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 2Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 3Health News:FDA Panel: Ban on Menthol Cigarettes Would Boost Health 4Health News:Teen Girls Who Befriend Boys at Higher Risk for Substance Abuse 2Health News:Orthodontic Retainers Can Harbor Harmful Microbes 2Health News:Japanese tsunami underscores need for elder disaster preparedness 2
The ACP 215 is the automated closed system cell processor with integrated process control....
... throughout the world are facing difficult times ... of the blood supply in the face ... donor base. Clearly, these centers must find ... manage their existing donor pools, and to ...
The Plasma Extractor is used to express blood components from collection containers. The spring-loaded front panel exerts pressure on the collection container causing the fluid to transfer until cont...
The Eppendorf Maxipettor is a continuously adjustable pipette for precise pipetting of volumes up to 10 ml (in 10 l increments). Even liquids with a high vapor pressure or viscosity can be pipetted w...
Medicine Products: